Opt-in Terms and Conditions

By submitting this form, I acknowledge all information I provided may be used by LEO Pharma Inc., its collaborators, affiliates and contracted service providers (collectively “LEO”) to provide me with additional information about products or services.

Once my health information has been disclosed to LEO, I understand that federal privacy laws may not protect it from further disclosure. However, LEO agrees to protect my health information by using and disclosing it only for the purposes allowed by me in this authorization or as otherwise allowed by law and will not sell or rent my information to any unauthorized parties or mailing lists.

I authorize LEO to contact me by mail, telephone, SMS text, or email with information about atopic dermatitis and products, promotions, services and research studies, and to ask my opinion about such information and topics, including market research and disease-related surveys.

I further authorize LEO to de-identify my health information and use it in performing research, education, business analytics, marketing studies or for other commercial purposes. I understand that different LEO parties may share identifiable health information with one another in order to de-identify it for these purposes and as needed to perform the Services or to send the communications listed above (the “Communications”).

I understand that I do not have to provide this information or receive the Communications, and that doing so will not affect my medical treatment, or access to health benefits or LEO medications. I may opt out of receiving Communications at any time by notifying a representative by calling 1-877-494-4536 or by sending a letter to LEO 7 Giralda Farms – 2nd Floor, Madison NJ 07940 USA. Questions or comments? Contact LEO US or call 1-877-494-4536

View Adbry™ Advocate™ Full Terms, Conditions, and Eligibility Criteria.

INDICATION AND IMPORTANT SAFETY INFORMATION

Read more Collapse

What is ADBRY?

ADBRY® (tralokinumab-ldrm) injection is a prescription medicine used to treat people 12 years of age and older with moderate-to-severe atopic dermatitis (eczema) that is not well controlled with prescription therapies used on the skin (topical), or who cannot use topical therapies. ADBRY can be used with or without topical corticosteroids.
It is not known if ADBRY is safe and effective in children under 12 years of age.

Do not use ADBRY if you are allergic to tralokinumab or to any of its ingredients.

What should I discuss with my healthcare provider before starting ADBRY?

Tell your healthcare provider about all your medical conditions, including if you:

have eye problems.
have a parasitic (helminth) infection.
are scheduled to receive any vaccinations. You should not receive a “live vaccine” if you are treated with ADBRY.
are pregnant or plan to become pregnant. It is not known whether ADBRY will harm your unborn baby. There is a pregnancy exposure registry for women who use ADBRY during pregnancy. The purpose of this registry is to collect information about the health of you and your baby. You or your healthcare provider can get information and enroll you in this registry by calling 1-877-311-8972 or visiting https://mothertobaby.org/ongoing-study/adbry-tralokinumab/.
are breastfeeding or plan to breastfeed. It is not known whether ADBRY passes into your breast milk and if it can harm your baby.

Tell your healthcare provider about all the medicines you take, including prescription and over-the-counter medicines, vitamins, and herbal supplements.

How should I use ADBRY?

See the detailed “Instructions for Use” that comes with ADBRY for information on how to prepare and inject ADBRY and how to properly store and throw away (dispose of) used ADBRY prefilled syringes.
Use ADBRY exactly as prescribed by your healthcare provider.
Your healthcare provider will tell you how much ADBRY to inject and when to inject it.
ADBRY comes as a single-dose (150 mg) prefilled syringe with needle guard.
ADBRY is given as an injection under the skin (subcutaneous injection).
If your healthcare provider decides that you or a caregiver can give the injection of ADBRY, you or your caregiver should receive training on the right way to prepare and inject ADBRY. Do not try to inject ADBRY until you have been shown the right way by your healthcare provider.
If you miss a dose, inject the missed dose as soon as possible, then continue with your next dose at your regular scheduled time.
If you inject too much ADBRY than prescribed, call your healthcare provider or call Poison Help line at 1-800-222-1222 or go to the nearest hospital emergency room right away.

Your healthcare provider may prescribe other medicines to use with ADBRY. Use the other prescribed medicines exactly as your healthcare provider tells you to.

What are the possible side effects of ADBRY?

ADBRY can cause serious side effects including:

Allergic reactions (hypersensitivity), including a severe reaction known as anaphylaxis. Stop using ADBRY and tell your healthcare provider or get emergency help right away if you get any of the following symptoms:
- breathing problems
- itching
- skin rash
- swelling of the face, mouth, and tongue
- fainting, dizziness, feeling lightheaded (low blood pressure)
- hives

Eye problems. Tell your healthcare provider if you have any worsening eye problems, including eye pain or changes in vision.

The most common side effects of ADBRY include:

Upper respiratory tract infections
Eye and eyelid inflammation, including redness, swelling, and itching
Injection site reactions
High count of a certain white blood cell (eosinophilia)

These are not all of the possible side effects of ADBRY. Call your doctor for medical advice about side effects. You may report side effects to FDA at 1-800-FDA-1088.

Please see full Prescribing Information, including Patient Information and Instructions for Use.